GlassScriptPhysician profile
Kelash Bajaj
NPI 1518220771
$244.44
in general payments reported to CMS, 2019-2025
7 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.21 · 2022: $39.52 · 2023: $32.75 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $127 · Food and Beverage: $42.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $126.94 |
| Food and Beverage | $42.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $96.04 | 2022-2025 | Imfinzi |
| Amgen INC. | $42.77 | 2025 | Imdelltra (Amg757) |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2023 | Iclusig |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
| Seagen INC. | $23.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.97 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelash Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.